Retatrutide FDA Approval Date: What to Expect in 2026-2027
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated March 2026
Retatrutide FDA Approval Date: What to Expect in 2026-2027
Key takeaways:
- Retatrutide is not FDA-approved as of March 2026. It is in Phase 3 clinical trials (the TRIUMPH program).
- The first Phase 3 results (February 2026) showed 28.7% weight loss. This exceeds the Phase 2 data.
- Realistic earliest FDA approval: mid-to-late 2027 (optimistic) to late 2028 (standard).
- Eli Lilly will likely submit an NDA after collecting sufficient Phase 3 data, potentially in mid-2027.
- The MASH (liver disease) indication could potentially move faster than the obesity indication.
- FDA-approved alternatives exist now: semaglutide (Wegovy) and tirzepatide (Zepbound).
Important: This article is for informational purposes only. Timelines discussed are estimates based on publicly available information and standard FDA processes. Retatrutide is an investigational compound. See our full medical disclaimer.
Where things stand right now (March 2026)
Retatrutide is in Phase 3 clinical trials. The first Phase 3 results were reported in February 2026 from the osteoarthritis trial (NCT05882045), showing 28.7% weight loss at the 12 mg dose. The primary obesity trial (NCT06383390) is still running.
No NDA has been submitted. No FDA review has started. We are still in the data collection phase.
For the full picture of what retatrutide is and how it works, see our complete 2026 retatrutide guide.
The FDA approval process, step by step
To understand the timeline, you need to understand how FDA drug approval works. Here is each stage and where retatrutide sits.
Phase 1 (Completed)
Safety testing in a small number of healthy volunteers. Retatrutide cleared this years ago. This stage established that the triple agonist mechanism was safe enough to continue testing.
Phase 2 (Completed)
Efficacy and dosing in patients with the target condition. The Phase 2 trial enrolled 338 adults with obesity and ran for 48 weeks. Results published in the New England Journal of Medicine (PMID: 37385275) showed 24.2% weight loss at the highest dose. This was the largest weight loss ever recorded in a controlled obesity trial.
Phase 3 (Currently underway)
Large, multi-site trials confirming efficacy and safety. This is where we are now. The TRIUMPH program includes at least 7 trials spanning obesity, type 2 diabetes, MASH, sleep apnea, and cardiovascular outcomes.
The first Phase 3 trial to report (obesity + knee osteoarthritis) showed 28.7% weight loss. The remaining trials are expected to read out throughout 2026.
NDA Submission (Estimated mid-2027)
After Phase 3 data is collected and analyzed, Eli Lilly compiles a New Drug Application (NDA). This is a massive document package containing all preclinical data, Phase 1-3 results, manufacturing processes, proposed labeling, and risk management plans.
NDA preparation typically takes 3-6 months after Phase 3 data is finalized.
FDA Review (10-12 months standard, 6-8 months priority)
The FDA assigns a review team to evaluate the NDA. Standard review takes 10-12 months. Priority Review (granted for drugs addressing significant unmet needs) takes 6-8 months.
Given the obesity epidemic and the strength of the data, Priority Review is plausible. But it is not guaranteed.
Advisory Committee (Optional)
The FDA may convene an advisory committee of external experts to review the data and vote on whether to recommend approval. This is common for novel mechanisms.
Decision
The FDA issues one of three outcomes: approval, a Complete Response Letter (requesting additional data), or rejection.
Precedent: how long did semaglutide and tirzepatide take?
Historical timelines give us a useful reference.
Semaglutide (Wegovy) timeline
| Milestone | Date |
|---|---|
| Phase 3 results (STEP 1) | February 2021 |
| NDA submission | December 2020 (rolling) |
| FDA approval | June 2021 |
| Time from Phase 3 readout to approval | ~4 months |
Semaglutide moved fast because Novo Nordisk used a rolling NDA submission, filing sections of the application as data became available. The strong data and well-understood GLP-1 mechanism helped.
Tirzepatide (Zepbound) timeline
| Milestone | Date |
|---|---|
| Phase 3 results (SURMOUNT-1) | April 2022 |
| NDA submission for obesity | October 2023 |
| FDA approval for obesity | November 2023 |
| Time from Phase 3 readout to obesity approval | ~19 months |
Tirzepatide took longer because Eli Lilly prioritized the diabetes indication first (Mounjaro, approved May 2022). The obesity approval came over a year after the pivotal data was published.
What this means for retatrutide
Eli Lilly has learned from the tirzepatide experience. The company now knows how the FDA evaluates GLP-1 class drugs for obesity. They have the regulatory infrastructure in place.
However, retatrutide is a triple agonist with a novel glucagon receptor component. The FDA may require more data or longer evaluation for this new mechanism. Or they may be satisfied with the extensive tirzepatide precedent and the GLP-1 class familiarity.
A rolling NDA submission (like Novo Nordisk used for semaglutide) could accelerate the timeline significantly.
The realistic timeline
Here is our best estimate based on publicly available data, historical precedent, and standard FDA processes.
| Milestone | Optimistic | Standard | Delayed |
|---|---|---|---|
| All key Phase 3 data in | Late 2026 | Mid 2027 | Late 2027 |
| NDA submission | Early 2027 | Late 2027 | Early 2028 |
| FDA review period | 6 months (priority) | 10-12 months | 10-12 months |
| FDA approval | Mid-late 2027 | Late 2028 | 2029 |
| Commercial availability | Weeks after approval | Weeks after approval | Weeks after approval |
Optimistic scenario: Phase 3 data reads out in late 2026. Eli Lilly uses a rolling NDA submission. FDA grants Priority Review. Approval arrives in mid-to-late 2027.
Standard scenario: Phase 3 data takes until mid-2027 to finalize. NDA submission in late 2027. Standard 10-12 month review. Approval in late 2028.
Delayed scenario: Unexpected safety signals, mixed results on one or more TRIUMPH trials, or FDA requests additional data. Approval pushed to 2029 or later.
Important: drug development timelines shift constantly. Manufacturing issues, regulatory questions, geopolitical factors, and FDA staffing can all affect the timeline.
The MASH fast track possibility
Here is a scenario most people are not tracking.
Retatrutide showed approximately 82% reduction in liver fat in Phase 2. If TRIUMPH-3 (the MASH trial) confirms these results, the liver disease indication could move faster than obesity.
Why? The MASH treatment landscape is thin. There are very few approved options for metabolic liver disease. The unmet medical need is enormous. This makes a Priority Review or even Breakthrough Therapy designation more likely for that specific indication.
If retatrutide is first approved for MASH rather than obesity, physicians could still prescribe it off-label for weight loss. This is how semaglutide first entered the weight loss market (Ozempic approved for diabetes, widely prescribed off-label for obesity before Wegovy was approved).
Watch the TRIUMPH-3 data closely. It could be the fastest path to retatrutide availability.
Likely brand name and pricing
Brand name
Eli Lilly has not announced a brand name for retatrutide. The company typically selects brand names during the NDA preparation phase. Expect two brand names, one for each primary indication (following the Mounjaro/Zepbound pattern for tirzepatide).
Pricing estimates
No official pricing has been announced. Here is what we can infer from market context:
| Factor | Estimate |
|---|---|
| Monthly list price | $1,000-1,500 |
| Positioning | Premium over tirzepatide |
| Insurance coverage | Unknown (depends on approval indication and payer negotiations) |
| Compounding | Not immediately available (patent-protected) |
| Savings programs | Likely (Eli Lilly offers them for tirzepatide) |
Eli Lilly will need to balance premium pricing (justified by superior efficacy data) against market adoption. If the price is too high relative to tirzepatide, insurance companies may not cover it as a first-line option.
The company's pricing strategy for tirzepatide (slightly below semaglutide at ~$1,060/month) suggests they may price retatrutide competitively to drive adoption.
What happens after approval
Once the FDA approves retatrutide, several things happen in sequence.
Prescription availability. Healthcare providers can prescribe it. Pharmacies begin stocking it. This typically happens within weeks of the approval announcement.
Insurance coverage negotiations. Pharmacy benefit managers and insurance companies negotiate coverage terms. This takes months. In the early period, many patients may pay out of pocket or use manufacturer savings programs.
Supply ramp-up. Manufacturing at scale takes time. Eli Lilly experienced significant supply shortages with tirzepatide after its approval. They will likely plan more aggressively for retatrutide, but initial supply constraints are possible.
Treatment guidelines update. Medical societies will update clinical practice guidelines to include retatrutide. This affects how physicians prescribe and how insurance companies justify coverage.
Market dynamics. Both semaglutide, tirzepatide, and retatrutide will coexist. Physicians will have three tiers of increasingly effective options. Step therapy protocols (try semaglutide first, then tirzepatide, then retatrutide) may become standard.
Alternatives while waiting
If you need obesity treatment now, waiting for retatrutide approval is not necessary.
Tirzepatide (Zepbound/Mounjaro): The most effective currently available option. Dual agonist (GLP-1 + GIP). About 22% average weight loss. Made by the same company as retatrutide. See our tirzepatide profile.
Semaglutide (Wegovy/Ozempic): The most widely prescribed GLP-1 agonist. About 15% average weight loss. Also reduces cardiovascular risk by 20%. See our semaglutide profile.
Clinical trials: If you want to potentially access retatrutide before approval, see our guide to enrolling in retatrutide clinical trials.
For a detailed comparison of all three compounds, see our retatrutide vs tirzepatide analysis and the semaglutide vs tirzepatide vs retatrutide data page.
For broader context on the regulatory landscape affecting peptides, see our FDA peptide regulations 2026 overview.
FAQ
When is the earliest retatrutide could be available by prescription?
The most optimistic realistic timeline puts FDA approval in mid-to-late 2027. This assumes Phase 3 data reads out in late 2026, Eli Lilly submits an NDA in early 2027, and the FDA grants Priority Review. A more conservative estimate is late 2028.
Is retatrutide FDA-approved for anything?
No. As of March 2026, retatrutide is not approved for any indication. It is an investigational compound in Phase 3 clinical trials.
Could the MASH indication be approved before obesity?
Possibly. The liver fat reduction data from Phase 2 was exceptional (82%), and the MASH treatment landscape has fewer existing options. This could make the MASH pathway faster than the obesity pathway. If approved for MASH first, physicians could prescribe it off-label for weight loss.
Will retatrutide be covered by insurance?
Unknown. Insurance coverage will depend on the approved indication, the negotiated price, and each insurer's formulary decisions. Based on the tirzepatide precedent, coverage is likely to start limited and expand over time. Eli Lilly will probably offer manufacturer savings programs.
What is the TRIUMPH program?
TRIUMPH is Eli Lilly's Phase 3 clinical trial program for retatrutide. It includes multiple trials studying the drug for obesity, type 2 diabetes, MASH (liver disease), sleep apnea, cardiovascular outcomes, and obesity with knee osteoarthritis.
Will retatrutide be more expensive than tirzepatide?
Likely, though not confirmed. Retatrutide is a more complex molecule with additional receptor activity. Eli Lilly will probably position it as a premium product. Industry estimates suggest $1,000-1,500 per month at launch, compared to ~$1,060 for tirzepatide.
Can I buy retatrutide online?
Products sold online as "retatrutide" are unregulated research chemicals. They have not been verified for purity, potency, or sterility. They are not manufactured to pharmaceutical standards. We do not recommend self-administering investigational compounds. The only legitimate access is through clinical trials.
Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Retatrutide is an investigational compound not approved by the FDA for any indication. Timeline estimates are based on publicly available information and are subject to change. Always consult a qualified healthcare provider for health decisions. See our full medical disclaimer.
Sources
- Jastreboff, A.M., et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." New England Journal of Medicine, 2023. PMID: 37385275
- Wilding, J.P.H., et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021. PMID: 33567185
- Jastreboff, A.M., et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022. PMID: 35658024
- NCT05882045: Retatrutide in Obesity with Knee Osteoarthritis. ClinicalTrials.gov
- NCT06383390: Retatrutide for Obesity (TRIUMPH). ClinicalTrials.gov
- U.S. Food and Drug Administration. "The Drug Development Process." FDA.gov. Updated 2024.
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.